Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners wit...

by Jake Rance, Lise Lafferty, Carla Treloar, the SToP-C Study Group
Published 2021-04-01

Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

by Nathan A Cannon, Maureen J Donlin, Xiaofeng Fan, Rajeev Aurora, John E Tavis, Virahep-C Study Group
Published 2008-05-01

Effect of pneumococcal conjugate vaccination on radiological findings in infants hospitalized with community acquired pneumonia in northern India

by S. Awasthi, C. Mani Pandey, T. Verma, N. Mishra, R. Chandra Shukla, N. Mohindra, A. Chauhan, M. Agarwal, N. Kohli, C. Study Group
Published 2020-12-01

Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.

by Maureen J Donlin, Nathan A Cannon, Rajeev Aurora, Jia Li, Abdus S Wahed, Adrian M Di Bisceglie, John E Tavis, Virahep-C Study Group
Published 2010-02-01

Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries

by Jan Tack, Vincenzo Stanghellini, Fermín Mearin, Yan Yiannakou, Peter Layer, Benoit Coffin, Magnus Simren, Jonathan Mackinnon, Gwen Wiseman, Anne Marciniak, on behalf of the IBIS-C Study group
Published 2019-05-01

Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – study protocol of a randomized controlled parallel...

by Christian A. Maiwald, Hendrik J. Niemarkt, Christian F. Poets, Michael S. Urschitz, Jochem König, Helmut Hummler, Dirk Bassler, Corinna Engel, Axel R. Franz, FiO2-C Study Group
Published 2019-10-01

Methods Used in Economic Evaluations of Chronic Kidney Disease Testing - A Systematic Review.

by Andrew J Sutton, Katie Breheny, Jon Deeks, Kamlesh Khunti, Claire Sharpe, Ryan S Ottridge, Paul E Stevens, Paul Cockwell, Philp A Kalra, Edmund J Lamb, eGFR-C study group
Published 2015-01-01

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

by Graham R Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K Rajender Reddy, Ludovico Tallarico, Mitchell L Shiffman, Silke Ahlers, Georgios Bakalos, Tarek Hassanein, GUARD-C Study Group
Published 2016-01-01

Predictors of self-reported symptoms and testing for COVID-19 in Canada using a nationally representative survey.

by Daphne C Wu, Prabhat Jha, Teresa Lam, Patrick Brown, Hellen Gelband, Nico Nagelkerke, H Chaim Birnboim, Angus Reid, Action to Beat Coronavirus in Canada/Action pour Battre le Coronavirus (Ab-C) Study Group
Published 2020-01-01

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

by Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, the DARLO‐C Study Group
Published 2020-06-01